BNVI Bionovo Inc. featured news, full reports, and detailed charts
Bionovo Inc. (BNVI) Wrap Up:
Bionovo, Inc. engages in the discovery and development of drugs in the areas of women’s health and cancer primarily in the United States. The company focuses on developing drugs to treat breast and ovarian cancers, and for menopause. Its lead drug candidate includes MF101, a receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause. Bionovo’s other products in development includes BZL101, an orally delivered anti-cancer agent for advanced breast cancer; and VG101, for the treatment of post-menopausal vulvar/vaginal dryness. It has collaborations with the University of California at San Francisco; University of California at Berkeley; Univers...Bionovo, Inc. (BNVI*(D):NASDAQ)
Snapshot of Bionovo, Inc. (BNVI)
|
OPEN
$0.42
|
PREVIOUS CLOSE
$0.42
|
|
|
DAY HIGH
$0.42
|
DAY LOW
$0.38
|
|
|
52 WEEK HIGH
09/3/09 - $1.15
|
52 WEEK LOW
12/31/08 - $0.17
|
|
|
MARKET CAP
40.9M
|
AVERAGE VOLUME 3 mo
367.8K
|
|
|
DILUTED EPS TTM
$-0.21
|
SHARES OUTSTANDING
107.5M
|
|
|
BNVI Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
BNVI Top Compensated Officers
Executives, Board Directors
Key developments for Bionovo, Inc. (BNVI)
Bionovo, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenues of $155,000. Loss from operations were $3,709,000 compared to $5,164,000 for the same period a year ago. Net loss was $3,726,000 compared to $5,058,000 for the same period a year ago. Basic and diluted net loss per common share was $0.05 compared to $0.07 for the same period a year ago. For the nine months, the company reported revenues of $162,000. Loss from operations were $12,441,000 compared to $13,734,000 for the same period a year ago. Net loss was $12,529,000 compared to $13,214,000 for the same period a year ago. Basic and diluted net loss per common share was $0.16 compared to $0.17 for the same period a year ago.
Bionovo Inc. announced the appointment of Steven R. Goldstein, M.D., to the company's Medical Advisory Board. Dr. Goldstein is a world leader on uterine safety. He has extensive experience in menopausal and perimenopausal uterine safety studies for several Selective Estrogen Receptor Modulators (SERMS). Dr. Steven Goldstein is the current Director of Gynecologic Ultrasound at New York University Medical Center; he is the current first Vice President of the American Institute of Ultrasound in Medicine.
Bionovo, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
BNVI Competitors
| Company | Last | Change | |
| No competitor information is available for BNVI. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | BNVI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 73.6x |
|
| Price/Book | 3.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 95.5x |
|
|
BNVI |
||
BNVI transactions
| Type Date |
Target |
|
Private Placement
October 2, 2009 |
-- |